Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE


Stay connected

Spotlight on rivoceranib

Come see the TKI selectivity comparison, the latest rivoceranib data, information on our pipeline, and more.

Learn how the mechanism of action of rivoceranib helps define its clinical potential.

Review our latest data

View the poster presentation

Abstract Title: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer

View the poster

See the phase 3 study results published in The Lancet

At ESMO 2022, we presented our proffered paper on the phase 3 study results comparing rivoceranib in combination with camrelizumab vs sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). Look how far we’ve come!

See the phase 3 study results published recently in The Lancet showing a statistically significant and clinically meaningful benefit in progression-free survival and overall survival.

Read the complete article

Stay connected

Sign up to receive important information about rivoceranib, company news and updates, or to connect with a member of our team.

Look for us at future events